These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29311509)

  • 1. 7-Azaindole: A Versatile Scaffold for Developing Kinase Inhibitors.
    Irie T; Sawa M
    Chem Pharm Bull (Tokyo); 2018; 66(1):29-36. PubMed ID: 29311509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-substituted azaindoles as potent inhibitors of Cdc7 kinase.
    Bryan MC; Falsey JR; Frohn M; Reichelt A; Yao G; Bartberger MD; Bailis JM; Zalameda L; Miguel TS; Doherty EM; Allen JG
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2056-60. PubMed ID: 23481650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and evaluation of 7-azaindole derivatives bearing benzocycloalkanone motifs as protein kinase inhibitors.
    Qhobosheane MA; Legoabe LJ; Josselin B; Bach S; Ruchaud S; Petzer JP; Beteck RM
    Bioorg Med Chem; 2020 Jun; 28(11):115468. PubMed ID: 32284225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
    Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
    Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
    Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
    Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and evaluation of a series of 4-azaindole-containing p21-activated kinase-1 inhibitors.
    Lee W; Crawford JJ; Aliagas I; Murray LJ; Tay S; Wang W; Heise CE; Hoeflich KP; La H; Mathieu S; Mintzer R; Ramaswamy S; Rouge L; Rudolph J
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3518-24. PubMed ID: 27346791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azaindole derivatives as potential kinase inhibitors and their SARs elucidation.
    Fang G; Chen H; Cheng Z; Tang Z; Wan Y
    Eur J Med Chem; 2023 Oct; 258():115621. PubMed ID: 37423125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus.
    Shaw SJ; Goff DA; Lin N; Singh R; Li W; McLaughlin J; Baltgalvis KA; Payan DG; Kinsella TM
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2617-2621. PubMed ID: 28408219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors.
    Feneyrolles C; Guiet L; Singer M; Van Hijfte N; Daydé-Cazals B; Fauvel B; Chevé G; Yasri A
    Bioorg Med Chem Lett; 2017 Feb; 27(4):862-866. PubMed ID: 28094183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of indirubin derivatives as new class of DRAK2 inhibitors from high throughput screening.
    Jung ME; Byun BJ; Kim HM; Lee JY; Park JH; Lee N; Son YH; Choi SU; Yang KM; Kim SJ; Lee K; Kim YC; Choi G
    Bioorg Med Chem Lett; 2016 Jun; 26(11):2719-23. PubMed ID: 27106709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.
    Daydé-Cazals B; Fauvel B; Singer M; Feneyrolles C; Bestgen B; Gassiot F; Spenlinhauer A; Warnault P; Van Hijfte N; Borjini N; Chevé G; Yasri A
    J Med Chem; 2016 Apr; 59(8):3886-905. PubMed ID: 27010810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel 7-azaindoles as PDK1 inhibitors.
    Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
    Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.
    Göring S; Taymans JM; Baekelandt V; Schmidt B
    Bioorg Med Chem Lett; 2014 Oct; 24(19):4630-4637. PubMed ID: 25219901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 1: design, synthesis and biological activity.
    Islam I; Bryant J; Chou YL; Kochanny MJ; Lee W; Phillips GB; Yu H; Adler M; Whitlow M; Ho E; Lentz D; Polokoff MA; Subramanyam B; Wu JM; Zhu D; Feldman RI; Arnaiz DO
    Bioorg Med Chem Lett; 2007 Jul; 17(14):3814-8. PubMed ID: 17531483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances of pyrrolopyridines derivatives: a patent and literature review.
    El-Gamal MI; Anbar HS
    Expert Opin Ther Pat; 2017 May; 27(5):591-606. PubMed ID: 28064544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design.
    Machiraju PK; Yedla P; Gubbala SP; Bohari T; Abdul JKV; Xu S; Patel R; Chittireddy VRR; Boppana K; Jagarlapudi SARP; Neamati N; Syed R; Amanchy R
    Comput Biol Chem; 2019 Jun; 80():374-383. PubMed ID: 31103918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding free-energy calculation is a powerful tool for drug optimization: calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β.
    Kitamura K; Tamura Y; Ueki T; Ogata K; Noda S; Himeno R; Chuman H
    J Chem Inf Model; 2014 Jun; 54(6):1653-60. PubMed ID: 24884406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 4-azaindoles as novel inhibitors of c-Met kinase.
    Porter J; Lumb S; Franklin RJ; Gascon-Simorte JM; Calmiano M; Riche KL; Lallemand B; Keyaerts J; Edwards H; Maloney A; Delgado J; King L; Foley A; Lecomte F; Reuberson J; Meier C; Batchelor M
    Bioorg Med Chem Lett; 2009 May; 19(10):2780-4. PubMed ID: 19369077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode.
    Gummadi VR; Rajagopalan S; Looi CY; Paydar M; Renukappa GA; Ainan BR; Krishnamurthy NR; Panigrahi SK; Mahasweta K; Raghuramachandran S; Rajappa M; Ramanathan A; Lakshminarasimhan A; Ramachandra M; Wong PF; Mustafa MR; Nanduri S; Hosahalli S
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4911-8. PubMed ID: 23880539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A unique hinge binder of extremely selective aminopyridine-based Mps1 (TTK) kinase inhibitors with cellular activity.
    Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Kojima E; Mitsuoka Y; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Yoshizawa H; Murai H; Nakamura Y
    Bioorg Med Chem; 2015 May; 23(9):2247-60. PubMed ID: 25801152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.